Individualizing pharmacologic and non-pharmacologic therapy for CKD associated with diabetes.

The review identifies multiple pharmacologic classes with kidney‑protective evidence in adults with diabetic kidney disease: renin–angiotensin system inhibitors (RASi), sodium–glucose cotransporter‑2 (SGLT2) inhibitors, glucagon‑like peptide‑1 receptor agonists (GLP‑1 RAs), and the nonsteroidal mineralocorticoid receptor antagonist finerenone. The authors emphasize that no head‑to‑head randomized controlled trial has directly compared these classes, and no Phase 3 trial has confirmed that specific multi‑class combinations improve hard outcomes beyond well‑selected monotherapy.

In parallel with drug options, the review stresses intensifying non‑pharmacologic measures: blood pressure control, individualized glycemic targets, moderation of sodium and protein intake, structured exercise, weight management, and smoking cessation. The authors propose a framework to individualize choices by selecting agents whose mechanisms address multiple concurrent clinical problems and by avoiding agents whose adverse effects conflict with the patient’s active comorbidities.

Combination approaches are described as biologically rational and are supported by additive albuminuria reduction seen in CONFIDENCE and by lifetime modeling, but the review notes that confirmation for hard outcomes is absent and that long‑term safety of sustained combination use has not been fully characterized. Until further trials are available, the authors recommend an individualized, monitoring‑based strategy that adapts through addition, temporary hold, or deprescribing based on clinical evolution.